Shannin Desroches fought for a diagnosis after being dismissed; She's been given a 5% chance of survival — but says "I don't ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...

Brandi DesMarais' 12-year fight with a rare liver tumor has been met with unwavering faith. Now her community is coming ...

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a ...

Innovative therapies and surgical techniques have the potential to transform liver cancer care. People with cirrhosis—a ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type.